



FOR IMMEDIATE RELEASE

Contact:
Jennifer Guinan
Sage Strategic Marketing
610-410-8111
Jennifer@sagestrat.com

Human Capital Consulting Partners Begins Contract for VGX Pharmaceuticals

Philadelphia, Pa., January 17, 2007—[Human Capital Consulting Partners](#) today announced a new human capital consulting client, [VGX Pharmaceuticals](#), a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases including HIV, hepatitis C virus, cancer, and inflammatory disease. Human Capital Consulting Partners will assist VGX Pharmaceuticals with its day-to-day human resources activities.

Three Neshaminy Interplex
Suite 301
Trevose, PA 19053
Office: 215-244-8110
Fax: 215-245-4705

"Fast-growing biopharmaceutical companies are primed to give serious consideration to the increasing importance of the role that human resources and human capital play in their long-term success," said Jim Geier, President of Human Capital Consulting Partners. "I look forward to this opportunity to assist VGX Pharmaceuticals in the development of human capital strategies and programs that best serve the company's vision and its employees and stakeholders.

About Human Capital Consulting Partners

Human Capital Consulting Partners helps companies grow by aligning their human capital strategy with their business strategy. The firm advises companies how to attract, develop, engage, and reward their people to attain operating success. The company acts as a trusted advisor to management, utilizing its global and board-level corporate experience to achieve big-picture impact through cultural change. Human Capital Consulting Partners analyzes business strategy, issues, and organizational dynamics and implements hands-on, practical, and results-oriented human capital strategies that drive business success. For more information, see www.hccpartners.com or call 251-244-8110.

About VGX Pharmaceuticals

[VGX Pharmaceuticals](#) is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases including HIV and hepatitis C virus (HCV) as well as cancer and inflammatory diseases. The company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, which are currently in Phase II clinical trials. In addition, a Phase I clinical trial will be initiated in 2007 for the company's lead cancer drug compound, VGX-150 for the treatment of Melanoma. Moreover, VGX Pharmaceuticals' therapeutic platform is designed to advance a strong and continual pipeline of additional drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027 and VGX-750 for inflammatory diseases currently in development. The product candidates and technology programs are protected by the company's extensive global intellectual property portfolio.